MEK'ing the Most of p53 Reactivation Therapy in Melanoma

作者：Lee John T; Herlyn Meenhard^*

来源：Journal of Investigative Dermatology, 2012, 132(2): 263-265.

DOI：10.1038/jid.2011.362

Melanoma is one of the few tumor types in which p53 is functionally repressed without extraneous mutations. With the number of kinasebased drug targets rapidly declining, p53 represents a relatively untapped resource for therapeutic intervention. Studies in other tumor types have demonstrated that reactivation of p53 is a viable strategy to initiate sustained tumor regression; combining p53 reactivation while inhibiting traditional genetic targets, such as mitogen-activated protein kinase/extracellular signalrelated kinase kinase (MEK), holds therapeutic promise.

• 出版日期2012-2